FDA Grants Orphan Drug Status To Mustang’s MB-101 CAR-T For Brain Cancers
Details : Mustang Bio MB-101 (IL13Ra2-targeted CAR T-cells) is being evaluated for the treatment of recurrent diffuse and anaplastic astrocytoma (astrocytomas) and glioblastoma.
Product Name : MB-101
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
July 07, 2025
Lead Product(s) : MB-101,MB-108
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MB-109 is Mustang’s designation for the treatment regimen combining MB-101 (COH-developed IL13Rα2‐targeted CAR-T cell therapy) with MB-108 (Nationwide-developed HSV-1 oncolytic virus), which is investigated for Recurrent Glioblastoma and High-Grade ...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : MB-101,MB-108
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MB-101
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : City of Hope
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MB-101, an IL13Rα2-targeted CAR T cell therapy demonstrate durable complete responses in GBM based on a 54-patient Phase 1 trial, as an optimized CAR T product incorporating enhancements in CAR design and T cell engineering to improve antitumor potency ...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 09, 2022
Lead Product(s) : MB-101
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : City of Hope
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
